Evercyte showing human telomerized cell alternatives at Alternatives to Animal Testing Congress
Press Release | Evercyte GmbH
SEPTEMBER 18, 2018
Vienna, Austria: – Innovative biotech manufacturer Evercyte will show how its human telomerized cells present a robust and reproducible in vitro system for cell based assays that can replace in vivo testing when it attends the 2018 European Congress on Alternatives to Animal Testing (EUSAAT) in Linz, Austria, later this month.
Evercyte scientists will deliver three key presentations to the conference that demonstrate various advantages of its technologies, based on its expertise in human telomerase immortalized cells and its abilities to produce high quality cell lines that comply with Good Cell Culture Practice (GCCP) standards.
iPSC-derived endothelial cells
The first Evercyte presentation will come on Day Two (September 24, 1830-2000) from researcher Zahra Mazidi who will present Poster 40 outlining latest progress on ‘Establishing endothelial cells derived from iPSCs for systemic sclerosis disease modeling and for in vitro vascular toxicity testing’.
Recent research has shown that human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs) exhibit functional heterogeneity that make them promising for study and treatment of a range of conditions, including vascular diseases.
During the free communications session (11:30 – 13:00 ) of Day Three of the Congress, Evercyte co-founder and CSO, Dr. Johannes Grillari will deliver a keynote address on ‘Cellular senescence: a response pathway within AOPs?’
Later, Evercyte´s CSO Johannes Grillari, will co-chair the 1400-1530 Session on Stem Cell Models (hiPS, ES, mES, miPS) in Hall 3.
In the evening session, the head of Evercyte’s Cell Immortalization Team, Dr. Matthias Wieser, will present a poster (No. 58) on “Highly relevant human in vitro cell models grown under serum-free culture conditions”. Dr. Wieser, an acknowledged expert in cell line development and engineering, will show that primary key functionalities upon life span extension of the cells are maintained and not changed.
Furthermore some of cells (such as Evercyte´s newly established HUVEC/TERT66 lines) can be cultivated serum-free, which meets “3R” principles by reducing animal components within cell culture media products.
“Reduction of animal testing is a cause close to our hearts and it is an arena in which Evercyte has a great deal to offer, thanks to our expertise in development of human cell lines and gene editing,” commented Dr. Johannes Grillari.
Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from immortalized or normal stem cells.
Recently, Evercyte has become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.
Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population by systematically establishing and commercializing relevant cell type specific model systems from donors of different genetic backgrounds.
About EUSAAT 2018
EUSAAT, the European Society for Alternatives to Animal Testing, is the leading European organization promoting the 3Rs Principle (refine – reduce – replace) in animal testing. It actively promotes the 1959 Russel and Burch principles outlined in “The Principles of Humane Experimental Technique” that proposed to reduce the number and the suffering of experimental animals by replacing them with advanced non-animal technologies.
EUSAAT offers expertise and networking, and supporting educational programs in close cooperation with NGOs, regulators, research institutions and industry to improve and implement humane experimental techniques as wells as advanced in silico und in vitro methods.
Its 21st European Congress, combined with 18th Annual Congress, is a four-day meeting opening September 23 at University of Linz in Austria.
The event is organized by EUSAAT with further details at: https://eusaat-congress.eu.
Irene Redlinghofer, Business Development and Project Management, Evercyte GmbH
Tel: +43 699 107 09 401
Click on Evercyte at EUSAAT 2018 for other information.
Click on Evercyte to contact the company directly.
Click on HUVEC/TERT66 leaflet for technical information.
Click on hTERT leaflet for technical information.
Click on Evercyte Product Catalog to download full details.